应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
01276 恒瑞医药
未开盘 01-14 16:08:06
79.100
+0.400
+0.51%
最高
80.950
最低
78.250
成交量
422.42万
今开
78.950
昨收
78.700
日振幅
3.43%
总市值
5,250亿
流通市值
204.08亿
总股本
66.37亿
成交额
3.36亿
换手率
1.64%
流通股本
2.58亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
恒瑞医药口服减重新药获批临床
健识局 · 01-14 19:08
恒瑞医药口服减重新药获批临床
港股开年上市潮涌 中资券商主导市场
中证金牛座 · 01-14 07:35
港股开年上市潮涌 中资券商主导市场
恒瑞前董事长空降、子公司单飞，先声药业“野心”渐露
达摩财经Pro · 01-13 22:51
恒瑞前董事长空降、子公司单飞，先声药业“野心”渐露
雅本化学：公司与恒瑞医药的合作模式为CDMO模式
证券日报 · 01-13 21:38
雅本化学：公司与恒瑞医药的合作模式为CDMO模式
GLP-1价格风暴：礼来2折“甩卖”替尔泊肽，国产药未上市先承压
华夏时报网 · 01-13 20:02
GLP-1价格风暴：礼来2折“甩卖”替尔泊肽，国产药未上市先承压
岁末年初，药企高管缘何密集迎人事变动？
21世纪经济报道 · 01-13 18:00
岁末年初，药企高管缘何密集迎人事变动？
智通AH统计|1月13日
智通财经 · 01-13 16:15
智通AH统计|1月13日
恒瑞医药(01276)： HRS-7535 片拟用于高血压合并超重或肥胖治疗获批开展临床试验
智通财经 · 01-12 22:45
恒瑞医药(01276)： HRS-7535 片拟用于高血压合并超重或肥胖治疗获批开展临床试验
A股越走越强引全球关注，瑞银报告：2026趋势上行，七大板块值得超配
智通财经网 · 01-12 22:16
A股越走越强引全球关注，瑞银报告：2026趋势上行，七大板块值得超配
JPM 2026前瞻 | 中国创新药站上全球舞台中央
Ofweek光电信息网 · 01-12 16:58
JPM 2026前瞻 | 中国创新药站上全球舞台中央
中国力量在JPM大会的闪耀时刻：24家国产企业双线发力
药渡 · 01-12 16:36
中国力量在JPM大会的闪耀时刻：24家国产企业双线发力
每日卖空追踪 | 恒瑞医药 01月12日卖空量成交14.1万股，卖空比例为6.72%
市场透视 · 01-12 16:30
每日卖空追踪 | 恒瑞医药 01月12日卖空量成交14.1万股，卖空比例为6.72%
恒瑞医药1类新药“富马酸立康可泮胶囊”上市申请获受理，靶向补体B因子助力PNH治疗
摩熵医药 · 01-12 16:25
恒瑞医药1类新药“富马酸立康可泮胶囊”上市申请获受理，靶向补体B因子助力PNH治疗
智通AH统计|1月12日
智通财经 · 01-12 16:15
智通AH统计|1月12日
医药生物行业跟踪周报：“十五五”聚焦脑机接口，抢占全球科技高地，建议关注：微创脑科学、翔宇医疗、美好医疗等【东吴医药朱国广团队】
国广有话说 · 01-11
医药生物行业跟踪周报：“十五五”聚焦脑机接口，抢占全球科技高地，建议关注：微创脑科学、翔宇医疗、美好医疗等【东吴医药朱国广团队】
恒瑞医药获小摩增持约112.78万股 每股作价约74.61港元
新浪港股 · 01-11
恒瑞医药获小摩增持约112.78万股 每股作价约74.61港元
替尔泊肽强势进军自免领域；针对 ADC，宜联与罗氏再度牵手；恒瑞、百济、默沙东、翰森…多款新药获批上市！｜Insight 新药周报
丁香园 Insight 数据库 · 01-11
替尔泊肽强势进军自免领域；针对 ADC，宜联与罗氏再度牵手；恒瑞、百济、默沙东、翰森…多款新药获批上市！｜Insight 新药周报
恒瑞医药：卡瑞利珠单抗在美国的BLA重新上市申报公司正在与FDA积极沟通
证券日报 · 01-09
恒瑞医药：卡瑞利珠单抗在美国的BLA重新上市申报公司正在与FDA积极沟通
恒瑞医药：公司前瞻性地广泛布局多个治疗领域，并向纵深发展
证券日报 · 01-09
恒瑞医药：公司前瞻性地广泛布局多个治疗领域，并向纵深发展
小摩增持恒瑞医药(01276)约112.78万股 每股作价约74.61港元
智通财经网 · 01-09
小摩增持恒瑞医药(01276)约112.78万股 每股作价约74.61港元
加载更多
公司概况
公司名称：
恒瑞医药
所属市场：
SEHK
上市日期：
--
主营业务：
江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。
发行价格：
--
{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":79.1,"timestamp":1768378086006,"preClose":78.7,"halted":0,"volume":4224192,"delay":0,"changeRate":0.005082592121982103,"floatShares":258000000,"shares":6637000000,"eps":1.1187542885659034,"marketStatus":"未开盘","change":0.4,"latestTime":"01-14 16:08:06","open":78.95,"high":80.95,"low":78.25,"amount":336107777,"amplitude":0.034307,"askPrice":79.1,"askSize":200,"bidPrice":79.05,"bidSize":7200,"shortable":3,"etf":0,"ttmEps":1.2979876756284696,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768440600000},"marketStatusCode":0,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":78.7,"openAndCloseTimeList":[[1768354200000,1768363200000],[1768366800000,1768377600000]],"volumeRatio":1.35111,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":63.61,"timestamp":1768374000000,"preClose":64.52,"halted":0,"volume":62925500,"delay":0,"premium":"+11.15"}},"requestUrl":"/m/hq/s/01276","defaultTab":"news","newsList":[{"id":"2603612637","title":"恒瑞医药口服减重新药获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2603612637","media":"健识局","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603612637?lang=zh_cn&edition=full","pubTime":"2026-01-14 19:08","pubTimestamp":1768388918,"startTime":"0","endTime":"0","summary":"1月12日晚间，恒瑞医药发布公告称，公司子公司山东盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS-7535片的《药物临床试验批准通知书》，将于近期开展临床试验，申请的适应症：本品拟用于高血压合并超重或肥胖治疗。目前全球范围内尚无口服小分子GLP-1R激动剂上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114192555a71a0828&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114192555a71a0828&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2543165471.USD","LU1023057109.AUD","LU0359201885.HKD","01276","LU0359202008.SGD","LU0359201612.USD","BK1191"],"gpt_icon":0},{"id":"2603265920","title":"港股开年上市潮涌 中资券商主导市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2603265920","media":"中证金牛座","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603265920?lang=zh_cn&edition=full","pubTime":"2026-01-14 07:35","pubTimestamp":1768347300,"startTime":"0","endTime":"0","summary":"回望2025年，港股一级市场热度空前，不仅在全球主要交易所中脱颖而出，而且IPO与再融资市场均展现出强劲活力。IPO方面，2025年共计117家公司在港股上市，其中主板116家，创业板1家，累计募资规模达2860亿港元。中资券商优势凸显2025年，港股一级市场备受全球瞩目，投行逐鹿香江，全球顶尖机构齐聚竞逐。中资券商强势主导市场，前十大股权承销排名中中资券商占有6席，合计市场份额超56%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114074138a4c0889f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114074138a4c0889f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03636","01810","01211","01776","03750","01641","00175","02050","BK1128","02259","01276"],"gpt_icon":1},{"id":"2603665117","title":"恒瑞前董事长空降、子公司单飞，先声药业“野心”渐露","url":"https://stock-news.laohu8.com/highlight/detail?id=2603665117","media":"达摩财经Pro","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603665117?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:51","pubTimestamp":1768315913,"startTime":"0","endTime":"0","summary":"在分拆子公司上市之际，又有市场消息称，前恒瑞医药董事长周云曙已履任先声药业总裁。不过，目前先声药业尚未官宣对周云曙的任命。2025年初至今，先声药业股价整体上涨，累计涨幅近74%。抗肿瘤业务“单飞”先声再明成立于2020年，是先声药业旗下的抗肿瘤创新药平台。由于研发成本较高，先声再明早早就显露出了“独立”迹象。随着创新药业务发展，先声药业的收入规模持续提升。当期，公司创新药营收已达到总营收的77.6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113225629a4bf5e30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113225629a4bf5e30&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","LU0359201612.USD","LU0359201885.HKD","LU0359202008.SGD","LU1023057109.AUD","LU2543165471.USD","01276","02096","BK1583"],"gpt_icon":0},{"id":"2603769682","title":"雅本化学：公司与恒瑞医药的合作模式为CDMO模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2603769682","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603769682?lang=zh_cn&edition=full","pubTime":"2026-01-13 21:38","pubTimestamp":1768311484,"startTime":"0","endTime":"0","summary":"证券日报网讯1月13日，雅本化学在互动平台回答投资者提问时表示，公司与恒瑞医药的合作模式为CDMO模式，覆盖恒瑞医药从临床前到商业化生产的各个阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133617688110.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828474.EUR","LU2580892789.USD","BK0174","LU1064130708.USD","LU1255011170.USD","LU1997245094.SGD","LU2543165471.USD","LU0405327494.USD","BK0183","BK0196","LU0359202008.SGD","LU1997244956.HKD","LU2097828805.USD","LU2289578879.USD","LU0359201612.USD","LU0405327148.USD","300261","LU1969619763.USD","LU2580892862.HKD","LU2097828557.USD","600276","LU1146622755.USD","LU1580142542.USD","LU2097828631.EUR","LU1328615791.USD","LU1997245177.USD","LU1655091616.SGD","LU1023057109.AUD","LU1820825898.SGD","LU2495084118.USD","01276","BK0028","LU1781817850.SGD","LU1064131003.USD","LU2488822045.USD","LU2148510915.USD","LU2097828714.EUR","CDMO","BK0060","LU0359201885.HKD","BK0012","LU2328871848.SGD","BK0239","BK0188","BK4139","BK1191","BK0229"],"gpt_icon":0},{"id":"2603668676","title":"GLP-1价格风暴：礼来2折“甩卖”替尔泊肽，国产药未上市先承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2603668676","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603668676?lang=zh_cn&edition=full","pubTime":"2026-01-13 20:02","pubTimestamp":1768305720,"startTime":"0","endTime":"0","summary":"2025年末至2026年初，国内GLP-1（胰高血糖素样肽-1）领域掀起一场颠覆性的价格风暴。随着礼来旗下核心产品替尔泊肽注射液（商品名：穆峰达）成功纳入国家医保目录，2型糖尿病每月治疗费用最低降至324．1元，较上市初期对应规格的月均2000元降幅超80%。近乎“两折”的医保定价让这款“全球药王”产品彻底走下高价神坛，竞争对手诺和诺德被迫跟进调价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601133617616496.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133617616496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1720051108.HKD","GB00BDT5M118.USD","IE00BJLML261.HKD","IE00BK4W5M84.HKD","LU0234572021.USD","LU1868836591.USD","LU1023059063.AUD","IE00B2B36J28.USD","LU0203201768.USD","LU1127390331.HKD","IE00BFTCPJ56.SGD","LU0471298694.HKD","LU0672654240.SGD","LU2750360997.AUD","IE00BJJMRY28.SGD","LU0353189763.USD","LU1712237335.SGD","LU2750360641.GBP","LU0289739699.SGD","LU2265009873.SGD","LU2471134952.CNY","LU0109391861.USD","LU1623119135.USD","LU1988902786.USD","IE00BWXC8680.SGD","LU0256863811.USD","LU1804176565.USD","SG9999001176.USD","LU1868837300.USD","IE00B1XK9C88.USD","BK4585","LU0316494557.USD","LU1868837136.USD","BK4533","LU0708995401.HKD","LU2456880835.USD","LU0006306889.USD","LU0203202063.USD","IE00BJJMRX11.SGD","LU1868836757.USD","LU0432979614.USD","LU0238689110.USD","IE00B775H168.HKD","IE00B1BXHZ80.USD","LU0820561818.USD","SGXZ99366536.SGD","LU2168564149.EUR","LU0320765992.SGD","SG9999014898.SGD","LU2462157665.USD","LU1064131342.USD","LU2491050071.SGD","LU0061475181.USD","LU2417539215.USD","LU1548497426.USD","LU1720051017.SGD","LU2491049909.HKD","01276","LU0823434740.USD","IE00BKDWB100.SGD","SG9999018865.SGD","LU2491050154.USD","LU0787776722.HKD","LU2236285917.USD","SG9999015945.SGD","IE0004445239.USD","LU2237438978.USD","LU2168564495.EUR","LU1814569148.SGD","LU2108987350.USD","LU2471134879.HKD","LU1280957306.USD","LU2361045086.USD","LU0943347566.SGD","LU2468319806.SGD","LU0353189680.USD","LU0882574139.USD","LU0820561909.HKD","IE00B7KXQ091.USD","LU1291159041.SGD","600276","LU1057294990.SGD","LU1267930730.SGD","LU2471134523.USD","IE00BK4W5L77.USD","LU1983299246.USD","LU2237443895.HKD","IE00BFSS7M15.SGD","LU2552382058.USD","SG9999013999.USD","LU1974910355.USD","LU2106854487.HKD","LU0456855351.SGD","IE00BFSS8Q28.SGD","LU1093756168.USD","LU2361044949.HKD","LU2461242641.AUD","LU2237443465.HKD","LU2237443382.USD","LU0096364046.USD","IE0002141913.USD","BK4588","LU0266013472.USD","LU2602419157.SGD","LU1232071149.USD","LU2237443622.USD","LU2357305700.SGD","LU0097036916.USD","LU0823434583.USD","SGXZ57979304.SGD","LU1366192091.USD","IE00B4R5TH58.HKD","LU2746668974.SGD","LU1868836914.USD","IE0009355771.USD","LU0114720955.EUR","LU1323610961.USD","LU2168564065.EUR","LU0466842654.USD","LU2211815571.USD","LU2552382215.SGD","LU2168564222.USD","SG9999014880.SGD","IE00BJT1NW94.SGD","LU0683600562.USD","LU0320765059.SGD","SG9999001176.SGD","SGXZ31699556.SGD","BK4007","LU1061106388.HKD","LU0471298777.SGD","LU0385154629.USD","LU1551013342.USD","LU2237443978.SGD","BK4516","LU0354030511.USD","IE00BKPKM429.USD","LU0823416689.USD","LU2264538146.SGD","LU2168563687.JPY","LU2112291526.USD","BK4144","BK4599","LU0889565916.HKD","IE00B4JS1V06.HKD","IE00BN29S564.USD","LU2471134796.USD","BK4534","IE0004445015.USD","LU0109394709.USD","LU2360106947.USD","SG9999018857.SGD","LU2361044865.SGD","LU1093756325.SGD","LU2237443549.SGD","SG9999014906.USD","SGXZ81514606.USD","LU0122379950.USD","LU0689472784.USD","BK4581","BK4590","LU1035775433.USD","LU2746668461.USD","SG9999015978.USD","LU0354030438.USD","LU1917777945.USD","LU0882574055.USD","SG9999015952.SGD","SG9999015986.USD","LU0094547139.USD","IE00BJJMRZ35.SGD","LU0106261372.USD","LU0256863902.USD","LU2324357040.USD","SG9999014914.USD","LU0198837287.USD","LU1989771016.USD","LU0640476718.USD","LU2023250504.SGD","LU0079474960.USD","LU0786609619.USD","LLY","LU0225283273.USD","LU2063271972.USD","LU2552382132.HKD","LU2087625088.SGD","LU2089984988.USD","LU0417517546.SGD","IE0005OL40V9.USD","LU1551013425.SGD","SG9999017495.SGD","SGXZ51526630.SGD","LU0323591593.USD","LU0058720904.USD","LU1069344957.HKD"],"gpt_icon":1},{"id":"2603550770","title":"岁末年初，药企高管缘何密集迎人事变动？","url":"https://stock-news.laohu8.com/highlight/detail?id=2603550770","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603550770?lang=zh_cn&edition=full","pubTime":"2026-01-13 18:00","pubTimestamp":1768298423,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者韩利明离职恒瑞医药（600276.SH）四年多后，周云曙的新任职动态浮出水面。日前，“江苏省肿瘤医院官方平台”发布消息显示，江苏省肿瘤医院（南京医科大学附属肿瘤医院）“江苏省恶性肿瘤先进诊疗重点实验室”与先声药业“神经与肿瘤药物研发全国重点实验室”正式签署战略合作协议，周云曙以“先声药业集团总裁”身份出席。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601133617514380.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133617514380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","LU1655091616.SGD","LU1146622755.USD","BK0239","BK0183","LU2097828805.USD","LU1064131003.USD","BK0060","LU1781817850.SGD","LU2289578879.USD","BK0012","06978","LU0359201885.HKD","LU2097828557.USD","LU2097828714.EUR","01276","BK1583","BK4080","LU0405327148.USD","BK0188","LU1064130708.USD","02096","LU1820825898.SGD","LU2097828631.EUR","LU0359202008.SGD","LU1328615791.USD","BK1574","BK4231","LU1969619763.USD","LU2543165471.USD","LU1997244956.HKD","LU2580892789.USD","LU1580142542.USD","LU1255011170.USD","600276","LU0359201612.USD","LU2580892862.HKD","ADC","LU1023057109.AUD","LU2148510915.USD","BK0196","LU2097828474.EUR","LU2495084118.USD","LU2488822045.USD","BK1191","LU1997245094.SGD","LU2328871848.SGD","LU0405327494.USD","BK0028","LU1997245177.USD"],"gpt_icon":0},{"id":"2603506092","title":"智通AH统计|1月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2603506092","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603506092?lang=zh_cn&edition=full","pubTime":"2026-01-13 16:15","pubTimestamp":1768292106,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止1月13日收盘，东北电气、浙江世宝、南京熊猫电子股份分列AH溢价率前三位，溢价率分别为800.00%、448.68%、279.68%；宁德时代、招商银行、恒瑞医药分列AH溢价率末三位，溢价率分别为-12.21%、-2.14%、-1.80%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392172.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0979878070.USD","LU0326950275.SGD","LU0488056044.USD","LU0791590937.USD","BK1214","LU0345780521.USD","IE00B3M56506.USD","LU0052750758.USD","LU1504937902.USD","LU0828238088.HKD","LU0348805143.USD","LU0039217434.USD","LU0918141887.USD","LU1769817096.USD","LU0516422366.SGD","LU1211504680.USD","LU0329678337.USD","LU1769817179.HKD","LU0231483743.USD","LU0287142896.SGD","LU0348816934.USD","IE00BMCWC346.EUR","LU1242518931.SGD","LU0417516902.SGD","BK1583","IE00B031J352.USD","LU0307460666.USD","BK1513","LU2125910500.SGD","399300","BK1554","LU1880383366.USD","000488","03968","BK1503","LU0328353924.USD","BK1594","LU1960683339.HKD","LU1880383440.USD","BK1546","LU1675838814.USD","LU1242518857.USD","LU0269904917.USD","LU0164880469.USD","BK1558","LU0106959298.USD","LU0823426308.USD","LU0886674414.USD","LU0516422952.EUR","BK1507","02691","LU0821914370.USD","LU1366334578.USD","LU2226246903.HKD","LU1008478684.HKD","LU2399975544.HKD","LU0067412154.USD","LU0823426480.USD","HK0000352382.USD","LU0890818403.SGD","SG9999002828.SGD","LU1328277881.USD","BK1221","SG9999006597.SGD","BK1147","BK1116","IE00B5MMRT66.SGD","BK1521","01812","IE00BYV24P56.USD","LU0359201885.HKD","LU0463099449.HKD","LU1023057109.AUD","LU1224709979.USD","LU1105468828.SGD","LU1282649810.SGD","LU2097828557.USD","LU1785774172.SGD","LU0163747925.USD","01057","00553","BK1183","LU0106252389.USD","LU0634319403.HKD","600036","BK1141","BK1610","LU0588546209.SGD","LU0348735423.USD","LU1152091168.USD","LU1152091754.HKD","HK0000352291.HKD","LU0048580855.USD","IE00BZ08YR35.GBP","BK1144","LU0061477393.USD","LU0348788117.USD","LU0348814723.USD","002202","LU0648948544.HKD","LU0880133367.SGD","LU1831875114.USD","LU2476274720.SGD","LU2543165471.USD","LU1993786604.SGD","LU1807302812.USD","LU0345780281.USD","LU0972618739.USD","LU0828237940.HKD","SG9999004220.SGD","300750","IE00BGHQDM52.EUR","LU0049853897.USD","LU0051755006.USD","LU0072913022.USD","LU0327786744.USD","IE00B29SXG58.USD","LU0871576103.HKD","LU2097828631.EUR","BK1149","600276","LU0469268626.HKD","LU0329678170.USD","BK1509","LU0543330566.HKD","LU2097828714.EUR","BK1170","LU1303224171.USD","IE00BVYPNP33.GBP","BK1516","BK1205","LU1048596156.SGD","LU1282648689.USD","LU1720050803.USD","LU2242644610.SGD","BK1191","LU0516423091.SGD","159982","LU0266512127.USD","LU0211977185.USD","LU1770034418.SGD","LU0370786039.SGD","IE00BZ08YT58.USD","BK1105","LU1282649141.HKD","LU0572944931.SGD","BK1544","LU0149721374.USD","LU0737861772.HKD","BK1514","LU0516422440.USD","LU0359202008.SGD","LU0181495838.USD","LU0791591158.USD","LU2097828805.USD","LU1961090484.USD","LU0737861699.HKD","IE00B543WZ88.USD","LU1688375341.USD","LU0509642566.USD","LU1808992512.USD","IE0008369823.USD","LU0140636845.USD","BK1501","LU0456846285.SGD","LU1655091616.SGD","LU2045819591.USD","01276","600775","LU0431992006.USD","LU0359201612.USD","LU2476274308.USD","LU0828237510.HKD","BK1592","LU1046422090.SGD","LU0164865239.USD","BK1237","BK1563","LU0315179316.USD","IE00BZ08YS42.EUR","BK1576","LU0117841782.USD","BK1562","LU1719994722.HKD","LU1188198961.HKD","BK1135","HK0000320264.USD","LU0173614495.USD","LU2778985437.USD","SG9999014674.SGD","BK1231","LU0708995583.HKD","BK1202","LU0348825331.USD","BK1560","LU0531971595.HKD","LU0228659784.USD","LU0589944569.HKD","IE0034224299.USD","IE00B0169L03.USD","IE0008368742.USD","LU0561508036.HKD","IE00BVYPNQ40.USD","LU2039709279.SGD","LU2097828474.EUR","HK0000306701.USD","LU1813983027.USD","HK0000306685.HKD","LU0228367735.SGD","LU0868486357.SGD","LU0502904849.HKD","CIHKY","LU0540923850.HKD","LU0229945570.USD","03750","LU0918141705.HKD","LU0266512473.USD","LU0455707207.USD","LU1366334651.USD","LU1115378108.SGD","002703","BK1526","BK1551","LU1481107354.HKD","LU0384037296.USD","BK1522","LU0456854461.SGD","LU0348827113.USD","LU0096374516.USD","BK1198","LU0501845795.SGD","LU0516423174.USD","03143","BK1171","LU0593848301.USD","00042","LU0456827905.SGD","BK1148","HK0000320223.HKD","IE0031814852.USD","IE00BF5LJ272.USD","BK1223","BK1163","LU0640798160.USD","LU1282649067.USD","LU0417516738.SGD","LU0320764599.SGD","LU0862451753.SGD","LU0314109678.HKD","LU1794554557.SGD","IE00B031HY20.USD","LU0797268264.HKD","LU1226287529.USD","BK1564","LU1251922891.USD","BK1505","LU0244354667.USD","SG9999002463.SGD"],"gpt_icon":1},{"id":"2602498075","title":"恒瑞医药(01276)： HRS-7535 片拟用于高血压合并超重或肥胖治疗获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2602498075","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602498075?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:45","pubTimestamp":1768229113,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 公布，近日，公司子公司山东盛迪医药有限公司收到国家药品监督管理局核准签发关于 HRS-7535 片的《药物临床试验批准通知书》，将于近期开展临床试验。根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 10 月 27 日受理的 HRS-7535 片符合药品注册的有关要求，同意本品开展临床试验。截至目前，HRS-7535 片相关项目累计研发投入约 36,940 万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1146622755.USD","LU1820825898.SGD","LU0405327494.USD","BK0060","BK0188","LU2097828474.EUR","LU2543165471.USD","LU1255011170.USD","LU1064131003.USD","LU2289578879.USD","BK0196","LU1781817850.SGD","LU0359201885.HKD","LU2097828714.EUR","LU0359202008.SGD","01276","LU2328871848.SGD","LU0405327148.USD","LU2580892862.HKD","LU2097828805.USD","BK0183","LU0359201612.USD","LU2495084118.USD","LU1969619763.USD","BK0028","LU2097828631.EUR","BK0239","BK0012","LU1023057109.AUD","BK1191","LU2097828557.USD","LU1997245177.USD","LU1064130708.USD","LU1997244956.HKD","LU1997245094.SGD","LU1580142542.USD","LU1655091616.SGD","LU2148510915.USD","600276","LU2488822045.USD","LU1328615791.USD","LU2580892789.USD"],"gpt_icon":0},{"id":"2603517547","title":"A股越走越强引全球关注，瑞银报告：2026趋势上行，七大板块值得超配","url":"https://stock-news.laohu8.com/highlight/detail?id=2603517547","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603517547?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:16","pubTimestamp":1768227365,"startTime":"0","endTime":"0","summary":"越走越强的A股正受到全球投资者的高度关注。上周末，瑞银发布最新研究报告，全面解读2026年A股市场的短期态势、全年逻辑与布局方向。瑞银判断，2026年A股正迎来新的上行趋势，资金与情绪全面回暖，与上市公司盈利支撑实现共振，市场结构性机会凸显。2026年科技自主可控、AI应用落地等趋势明确，成长板块盈利增速优势显著，将持续成为市场主线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112222148a711fbf4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112222148a711fbf4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0417516738.SGD","LU1720050803.USD","LU0348825331.USD","01276","00300","BK1224","LU0417516902.SGD","LU1794554557.SGD","LU0348735423.USD","01880"],"gpt_icon":0},{"id":"2602933518","title":"JPM 2026前瞻 | 中国创新药站上全球舞台中央","url":"https://stock-news.laohu8.com/highlight/detail?id=2602933518","media":"Ofweek光电信息网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602933518?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:58","pubTimestamp":1768208280,"startTime":"0","endTime":"0","summary":"2026年第44届摩根大通医疗健康大会将于1月12日至15日在美国旧金山举行。据披露，本届JPM的议题与参会企业或将高度集中于六大核心领域，其中生物技术板块占比最高，预计接近35%。目前，已有多家国内企业确认参会，且覆盖CXO与创新药两大核心群体。从行业趋势看，本届JPM或将进一步强化两条技术主线。进入2026年，这一趋势仍在延续。宜联生物B7H3 ADC授权给罗氏此次JPM 2026将成为国内药企集中展示核心分子竞争力、推动海外BD合作的重要窗口。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112173836a710ffe8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112173836a710ffe8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06160","02269","LU2328871848.SGD","03696","BK1583","06978","09995","02359","BK1161","LU1969619763.USD","09688","01530","01276","02615"],"gpt_icon":0},{"id":"2602902425","title":"中国力量在JPM大会的闪耀时刻：24家国产企业双线发力","url":"https://stock-news.laohu8.com/highlight/detail?id=2602902425","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602902425?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:36","pubTimestamp":1768206992,"startTime":"0","endTime":"0","summary":"而今年，中国力量成为舞台上最耀眼的星光之一：24家国产医药企业集体亮相，以“主会场引领、亚太专场扩容”的双线布局，向世界展示中国医药产业的创新硬实力与全球化野心。结 语从主会场的核心发声到亚太专场的集体亮相，24家中国药企在JPM大会的舞台上，用实打实的研发成果、商业化突破与海外合作，书写着中国医药的全球化篇章。这不仅是中国力量的闪耀时刻，更预示着2026年中国创新药将在全球舞台上迎来更多突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112165035a710cae5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112165035a710cae5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1719994722.HKD","LU2328871848.SGD","BK1161","BK1588","LU2488822045.USD","LU1303224171.USD","LU0307460666.USD","BK1574","LU1770034418.SGD","02359","BK1583","01530","BK1500","06990","09995","06160","09688","LU1969619763.USD","LU0588546209.SGD","02269","01276","06978","LU1251922891.USD"],"gpt_icon":0},{"id":"2603522109","title":"每日卖空追踪 | 恒瑞医药 01月12日卖空量成交14.1万股，卖空比例为6.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603522109","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603522109?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:30","pubTimestamp":1768206618,"startTime":"0","endTime":"0","summary":"恒瑞医药北京时间01月12日，涨0.26%，卖空量成交14.1万股，较上一交易日减少52.75%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112164641a4b9d193&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112164641a4b9d193&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","LU0359201885.HKD","LU2543165471.USD","LU1023057109.AUD","LU0359202008.SGD","BK1191","01276"],"gpt_icon":0},{"id":"2603221745","title":"恒瑞医药1类新药“富马酸立康可泮胶囊”上市申请获受理，靶向补体B因子助力PNH治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2603221745","media":"摩熵医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603221745?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:25","pubTimestamp":1768206326,"startTime":"0","endTime":"0","summary":"1月9日，恒瑞医药对外发布公告称，其自主研发的1类新药——富马酸立康可泮胶囊的药品上市许可申请已正式获得受理。该试验旨在评价富马酸立康可泮胶囊在既往未接受过补体抑制剂治疗的PNH患者中的有效性和安全性。图源：摩熵医药-全球药物研发数据库研究结果表明，富马酸立康可泮胶囊在提高PNH患者的血红蛋白水平、避免输血需求以及改善患者疲劳症状等方面均表现出优于C5补体抑制剂的疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112171020a4b9ece8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112171020a4b9ece8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","LU0359201612.USD","LU2543165471.USD","LU0359201885.HKD","LU1023057109.AUD","01276","LU0359202008.SGD"],"gpt_icon":0},{"id":"2602925995","title":"智通AH统计|1月12日","url":"https://stock-news.laohu8.com/highlight/detail?id=2602925995","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602925995?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:15","pubTimestamp":1768205705,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止1月12日收盘，东北电气、浙江世宝、南京熊猫电子股份分列AH溢价率前三位，溢价率分别为770.97%、432.48%、288.23%；宁德时代、招商银行、恒瑞医药分列AH溢价率末三位，溢价率分别为-12.93%、-2.18%、-0.61%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0737861772.HKD","BK1141","HK0000306685.HKD","LU1211504680.USD","LU1282649141.HKD","LU1808992512.USD","LU1880383440.USD","SG9999012736.USD","LU1993786604.SGD","LU0455707207.USD","BK1198","BK1560","BK1584","BK1554","LU0821914370.USD","LU0431992006.USD","CIHKY","LU0052750758.USD","LU0164880469.USD","LU0862451753.SGD","LU0370786039.SGD","LU0140636845.USD","LU0244354667.USD","LU0359202008.SGD","LU1961090484.USD","LU2097828631.EUR","600775","LU0640798160.USD","LU1188198961.HKD","LU1046422090.SGD","SG9999012710.SGD","LU1366334651.USD","LU0589944569.HKD","LU1504937902.USD","LU2097828714.EUR","000488","LU0231483743.USD","LU0307460666.USD","BK1521","LU1115378108.SGD","HK0000352382.USD","LU0918141887.USD","BK1105","IE00B3M56506.USD","LU0049853897.USD","LU0791590937.USD","LU0287142896.SGD","IE00B031HY20.USD","LU0828237510.HKD","LU1688375341.USD","BK1149","LU0572939691.SGD","LU1960683339.HKD","LU0348814723.USD","LU0417516738.SGD","LU0106959298.USD","LU0348788117.USD","SG9999002828.SGD","LU0868486357.SGD","LU0890818403.SGD","600036","LU0463099449.HKD","LU1366334578.USD","LU0502904849.HKD","BK1564","LU2242644610.SGD","BK1513","LU1251922891.USD","LU0348805143.USD","03968","LU0348816934.USD","LU0634319403.HKD","LU0320764599.SGD","LU2226246903.HKD","LU1242518857.USD","LU0561508036.HKD","LU2125910500.SGD","LU0516423174.USD","LU2476274308.USD","LU1242518931.SGD","SG9999002463.SGD","LU0329678337.USD","IE00B5MMRT66.SGD","159982","LU0972618739.USD","LU2097828474.EUR","LU0345780281.USD","IE00BZ08YT58.USD","LU0072913022.USD","LU0516423091.SGD","LU0918141705.HKD","LU1813983027.USD","LU2476274720.SGD","LU0314109678.HKD","LU0886674414.USD","LU0572944931.SGD","BK1546","LU1023057109.AUD","LU2778985437.USD","BK1526","BK1202","IE0008368742.USD","LU0211977185.USD","LU0501845795.SGD","LU1807302812.USD","BK1505","BK1507","HK0000320264.USD","LU0181495838.USD","LU0264606111.USD","LU0315179316.USD","LU0345780521.USD","LU1008478684.HKD","LU1720050803.USD","LU0266512127.USD","LU0359201612.USD","BK1583","SG9999014674.SGD","IE0032431581.USD","BK1610","LU0708995583.HKD","LU0163747925.USD","LU1794554557.SGD","SG9999004220.SGD","BK1184","BK1509","LU0823426480.USD","BK1237","LU0061477393.USD","01812","LU0648948544.HKD","BK1516","LU0348825331.USD","LU1226287529.USD","LU0348735423.USD","LU2039709279.SGD","BK1148","LU0229945570.USD","LU0329678170.USD","LU2045819591.USD","BK1191","LU0509642566.USD","LU0456827905.SGD","BK1163","HK0000320223.HKD","IE0034224299.USD","LU0348827113.USD","SG9999006597.SGD","BK1550","LU1105468828.SGD","HK0000306701.USD","LU0384037296.USD","03143","LU0106252389.USD","LU0266512473.USD","BK1116","LU0516422366.SGD","LU0516422440.USD","BK1514","LU0067412154.USD","LU0593848301.USD","002703","300750","BK1147","LU0327786744.USD","LU0979878070.USD","LU1282648689.USD","LU0572940350.SGD","LU1770034418.SGD","LU0797268264.HKD","LU2097828557.USD","LU0823426308.USD","IE00BVYPNP33.GBP","LU0488056044.USD","LU1303224171.USD","BK1592","BK1501","LU0164865239.USD","LU1785774172.SGD","BK1214","BK1170","IE00B031J352.USD","LU1769817179.HKD","BK1231","LU1719994722.HKD","LU0228659784.USD","LU0359201885.HKD","LU0540923850.HKD","LU0269904917.USD","LU0516422952.EUR","LU1152091754.HKD","LU0051755006.USD","LU1769817096.USD","IE00BYV24P56.USD","SG9999012744.USD","LU1481107354.HKD","HK0000352291.HKD","LU0543330566.HKD","IE00B0169L03.USD","02691","LU1328277881.USD","IE0008369823.USD","IE0031814852.USD","BK1183","399300","01276","BK1144","IE00B29SXG58.USD","01057","HK0000165453.HKD","LU1831875114.USD","600276","BK1137","LU0117841782.USD","BK1551","LU0828238088.HKD","IE00BGHQDM52.EUR","LU2543165471.USD","LU0469268626.HKD","LU0588546209.SGD","LU0880133367.SGD","BK1171","LU1048596156.SGD","IE00BF5LJ272.USD","BK1205","LU0048580855.USD","LU0456846285.SGD","IE00BVYPNQ40.USD","LU0791591158.USD","LU2097828805.USD","LU0417516902.SGD","LU2399975544.HKD","BK1576","LU0096374516.USD","BK1544","IE00B543WZ88.USD","LU0228367735.SGD","00042","BK1558","LU0173614495.USD","LU1152091168.USD","IE00BZ08YR35.GBP","LU0737861699.HKD","LU1282649810.SGD","LU1880383366.USD","LU1282649067.USD","LU0326950275.SGD","LU0039217434.USD","LU0871576103.HKD","LU0456854461.SGD","BK1562","002202","00553","LU1675838814.USD","LU0328353924.USD","LU0828237940.HKD","IE00BMCWC346.EUR","IE00BZ08YS42.EUR","SG9999012728.SGD","LU0531971595.HKD","LU1224709979.USD","BK1594","BK1223","LU1655091616.SGD","BK1522","LU0149721374.USD"],"gpt_icon":1},{"id":"2602559242","title":"医药生物行业跟踪周报：“十五五”聚焦脑机接口，抢占全球科技高地，建议关注：微创脑科学、翔宇医疗、美好医疗等【东吴医药朱国广团队】","url":"https://stock-news.laohu8.com/highlight/detail?id=2602559242","media":"国广有话说","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602559242?lang=zh_cn&edition=full","pubTime":"2026-01-11 21:24","pubTimestamp":1768137841,"startTime":"0","endTime":"0","summary":"海内外共振，加速抢占全球科技高地：脑机接口技术当前已经成为全球各国科技竞争的战略高地之一。当前全球脑机接口真处于爆发前夜，我国脑机接口产业有望迎来黄金发展期，建议关注微创脑科学、翔宇医疗、美好医疗等。从自免角度，建议关注康诺亚、益方生物、一品红等。从创新药龙头角度，建议关注百济神州、恒瑞医药等。从医疗器械角度，建议关注联影医疗、鱼跃医疗等。从中药角度，建议关注佐力药业、方盛制药、东阿阿胶等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111213058a70ddf1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111213058a70ddf1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","02228","BK1161","BK1141","BK1515","02172","BK1574","09926","02615","BK1100","03933","BK1617","09995","09939"],"gpt_icon":0},{"id":"2602383553","title":"恒瑞医药获小摩增持约112.78万股 每股作价约74.61港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602383553","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602383553?lang=zh_cn&edition=full","pubTime":"2026-01-11 16:24","pubTimestamp":1768119840,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 香港联交所最新资料显示，1月6日，小摩增持恒瑞医药（01276）112.7828万股，每股作价74.6126港元，总金额约为8415.02万港元。增持后最新持股数目约为1919.4万股，最新持股比例为7.43%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-01-11/doc-inhfxmcp3824639.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1064131342.USD","LU1244550577.SGD","IE00BLSP4452.SGD","LU2211815571.USD","LU1894683348.USD","IE00BBT3K403.USD","LU0106831901.USD","LU0820561909.HKD","LU0417517546.SGD","LU2213496289.HKD","LU2237443549.SGD","IE00BHPRN162.USD","LU0820561818.USD","LU1894683264.USD","LU2580892862.HKD","LU1668664300.SGD","LU2097828805.USD","IE000M9KFDE8.USD","LU0211328371.USD","IE00BN8TJ469.HKD","LU0323591593.USD","LU2552382132.HKD","01276","IE00B1BXHZ80.USD","BK0183","600276","LU0238689110.USD","LU0070302665.USD","LU0256863811.USD","LU0820562030.AUD","LU2097828714.EUR","LU0345769631.USD","LU2552382058.USD","LU0787776722.HKD","LU2097828631.EUR","LU2237443622.USD","LU2417539215.USD","LU0251132253.USD","BK0188","LU1162221912.USD","LU2505996681.GBP","LU0203345920.USD","LU0265550359.USD","BK4516","LU0320765489.SGD","LU2430703095.HKD","LU0868494708.USD","BK0196","LU2456880835.USD","IE00BJLML261.HKD"],"gpt_icon":0},{"id":"2602523551","title":"替尔泊肽强势进军自免领域；针对 ADC，宜联与罗氏再度牵手；恒瑞、百济、默沙东、翰森…多款新药获批上市！｜Insight 新药周报","url":"https://stock-news.laohu8.com/highlight/detail?id=2602523551","media":"丁香园 Insight 数据库","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602523551?lang=zh_cn&edition=full","pubTime":"2026-01-11 14:03","pubTimestamp":1768111391,"startTime":"0","endTime":"0","summary":"下文，Insight 将分别摘取本周国内外部分重点项目进展做介绍。因 Insight 数据库持续高速更新，不同时段检索结果可能存在时效性差异，请以最新查询为准。这是首个证实治疗肥胖可改善银屑病关节炎疾病指标的对照药理学研究。安全性方面，接受依奇珠单抗和替尔泊肽联合治疗的受试者中，不良事件通常为轻度至中度，且不良事件类型与每种药物已知的安全性特征一致。病毒性肝炎作为全球第二大传染病致死原因，其中高达 83% 的死亡病由乙肝导致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111142818a4b5f7e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111142818a4b5f7e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03692","BK1589","LU2543165471.USD","LU0359201885.HKD","01276","LU0359202008.SGD","BK1583","LU1023057109.AUD","BK1191","LU0359201612.USD"],"gpt_icon":0},{"id":"2602375349","title":"恒瑞医药：卡瑞利珠单抗在美国的BLA重新上市申报公司正在与FDA积极沟通","url":"https://stock-news.laohu8.com/highlight/detail?id=2602375349","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602375349?lang=zh_cn&edition=full","pubTime":"2026-01-09 20:33","pubTimestamp":1767962029,"startTime":"0","endTime":"0","summary":"证券日报网讯1月9日，恒瑞医药在互动平台回答投资者提问时表示，卡瑞利珠单抗在美国的BLA重新上市申报公司正在与FDA积极沟通，相关事项如有进展公司将严格按照相关规定进行公告，履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601093614449751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0405327148.USD","LU1064131003.USD","LU2488822045.USD","LU2097828805.USD","LU1655091616.SGD","LU2097828631.EUR","LU0359202008.SGD","BK0196","BK0060","LU1969619763.USD","LU2097828714.EUR","LU2495084118.USD","01276","LU1997244956.HKD","BK0012","BK1191","LU1023057109.AUD","LU2580892789.USD","LU2580892862.HKD","LU1580142542.USD","LU2097828474.EUR","LU0359201612.USD","BK0183","BK0239","LU1781817850.SGD","LU2148510915.USD","LU0405327494.USD","LU1820825898.SGD","LU2328871848.SGD","600276","LU1146622755.USD","LU1997245094.SGD","LU1997245177.USD","LU1328615791.USD","LU2543165471.USD","LU1255011170.USD","LU2097828557.USD","LU2289578879.USD","BK0028","LU1064130708.USD","BK0188","LU0359201885.HKD"],"gpt_icon":0},{"id":"2602378049","title":"恒瑞医药：公司前瞻性地广泛布局多个治疗领域，并向纵深发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2602378049","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602378049?lang=zh_cn&edition=full","pubTime":"2026-01-09 20:05","pubTimestamp":1767960346,"startTime":"0","endTime":"0","summary":"证券日报网讯1月9日，恒瑞医药在互动平台回答投资者提问时表示，公司前瞻性地广泛布局多个治疗领域，并向纵深发展。公司在肿瘤领域有丰富的研发管线，与此同时，在代谢和心血管疾病、免疫和呼吸系统疾病、神经科学等领域也进行了广泛布局，打造长期发展的多元化战略支柱。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601093614409744.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","LU1023057109.AUD","LU1997245177.USD","LU0359202008.SGD","LU2580892862.HKD","LU1781817850.SGD","LU2328871848.SGD","01276","LU2097828631.EUR","BK0239","LU2495084118.USD","LU2097828557.USD","LU0359201612.USD","LU0405327148.USD","BK0028","LU1997245094.SGD","BK0012","BK0060","600276","LU1064131003.USD","LU1655091616.SGD","LU2097828714.EUR","LU1969619763.USD","LU2097828474.EUR","LU2148510915.USD","BK1191","LU1328615791.USD","LU1064130708.USD","LU2543165471.USD","LU1997244956.HKD","LU0359201885.HKD","LU0405327494.USD","BK0183","LU2097828805.USD","LU2289578879.USD","LU2580892789.USD","BK0188","LU1146622755.USD","BK0196","LU1255011170.USD","LU1580142542.USD","LU1820825898.SGD"],"gpt_icon":0},{"id":"2602547378","title":"小摩增持恒瑞医药(01276)约112.78万股 每股作价约74.61港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602547378","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602547378?lang=zh_cn&edition=full","pubTime":"2026-01-09 19:29","pubTimestamp":1767958148,"startTime":"0","endTime":"0","summary":"1月6日，小摩增持恒瑞医药(01276)112.7828万股，每股作价74.6126港元，总金额约为8415.02万港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260109/20260109193002_54761.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260109/20260109193002_54761.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391107.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1064131342.USD","IE00BLSP4239.USD","LU2097828805.USD","LU2357305700.SGD","LU1084165304.USD","BK4533","IE00BKVL7J92.USD","LU1244550494.USD","LU1255011170.USD","LU2237443549.SGD","IE0034235295.USD","LU0417517546.SGD","LU1328615791.USD","LU1551013342.USD","IE00BLSP4452.SGD","LU2242649171.HKD","LU1720051108.HKD","LU1668664300.SGD","LU1548497426.USD","LU0234572021.USD","LU0405327148.USD","LU1146622755.USD","LU1894683264.USD","LU0215105999.USD","LU2023250330.USD","600276","BK0196","LU0689472784.USD","LU1974910355.USD","LU1720051017.SGD","LU1145028129.USD","LU1267930490.SGD","LU2264538146.SGD","LU0256863811.USD","IE00BJTD4V19.USD","LU2756315664.SGD","IE00BDRTCR15.USD","01276","LU0971096721.USD","BK4550","LU1997244956.HKD","LU2746668461.USD","LU2580892789.USD","LU1116320737.USD","LU0640476718.USD","LU0323591593.USD","LU0820561818.USD","LU1119994496.HKD","BK0012","LU2552382215.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":0.0174},{"period":"1month","weight":0.0933},{"period":"3month","weight":-0.0354},{"period":"6month","weight":0.0836},{"period":"1year","weight":0.7957},{"period":"ytd","weight":0.1102}],"compareEarnings":[{"period":"1week","weight":0.0204},{"period":"1month","weight":0.0535},{"period":"3month","weight":0.0429},{"period":"6month","weight":0.0876},{"period":"1year","weight":0.4048},{"period":"ytd","weight":0.0534}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}